Combined Fulvestrant and Anastrozole as Neo-adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer
18 Years
N/A
Female
Invasive Breast Cancer
Trial Information
Combined Fulvestrant and Anastrozole as Neo-adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer
Hormonal therapies are generally preferred treatments of breast cancer because they have
minimal side effects. Hormone receptor positive breast cancer generally does not respond
very well to chemotherapy, which has many side effects. Hormonal therapy with a single drug
such as Anastrozole is the main type of treatment used to reduce the risk of cancer
recurrence. Whether a combination of Anastrazole nad Fulvestrant is effective and feasible
is not known. This study is being done to answer this question.
This is a phase II single arm study. Patients will have an Oncotype Dx performed and only if
the recurrence score is low or intermediate, they would be eligible. Eligible patients will
receive Anastrazole and Fulvestrant for 16 week.
Subjects will receive Anastrazole 1 mg po q day and Fulvestrant 500 mg IM, day 1, day 14,
day 28 and thereafter once every 28 days on outpatient basis. On day 28, subjects will be
evaluated for side effects and clinically and a needle core biopsy (optional) will be
obtained. If there is increase in Ki 67 by 50%, subjects will be taken off the study.
Response evaluation will occur every 28 days during outpatient clinic visits. All treatment
will continue until 4 months when patients will undergo surgical intervention. After
surgery, patients will be off study and will receive additional breast cancer therapy at the
discretion of their treating physician. Patients who develop progressive disease on protocol
will be removed from the study and will then be treated at the discretion of the treating
physician. The protocol will be closed after the last accrued patient has had surgery.
Inclusion Criteria
Inclusion criteria
- Female patient > 18 years of age.
- Histologically proven invasive adenocarcinoma of the breast.
- Patients must be candidates for neoadjuvant treatment (Tumor size > 2cm and/or
clinical N1 or N2).
- ER positive (> 10% of cells) and/or PgR positive (> 10% of the cells) and HER-2
negative disease (IHC 0 or 1+ and/or FISH negative, IHC 2+ and FISH negative)
- Menopausal status
- Patients must be post-menopausal as defined by one of the following criteria:
- Prior bilateral oophorectomy
- 12 months since LMP with no prior hysterectomy
- Patients > 55 years with prior hysterectomy
- Patients < 55 years of age and with a prior hysterectomy without
oophorectomy, estradiol and FSH levels must be consistent with the patient
being postmenopausal.
- Premenopausal or perimenopausal women who do not meet the postmenopausal
criteria above are also eligible, but are required to undergo ovarian
suppression with an LHRH agonist. Ovarian suppression can be initiated any time
prior to or on day 1 of protocol therapy and must continue throughout protocol
therapy.
- Performance status of 2 or better per SWOG criteria
- No prior chemotherapy or endocrine therapy for the current cancer diagnosis.
- If female of childbearing potential, pregnancy test is negative prior to initiation
of ovarian suppression.
- Patients must be informed of the investigational nature of the study, and must sign
an informed consent in accordance with the institutional rules.
- Oncotype Dx Recurrence Score < 25.
Exclusion criteria
- Patients with metastatic disease.
- The presence of any other medical or psychiatric disorder that, in the opinion of the
treating physician, would contraindicate the use of drugs in this protocol or place
the subject at undue risk for treatment complications.
- Premenopausal without ovarian suppression.
- Pregnancy or lactation.
- Patients with concomitant or previous malignancies within the last 5 years, with the
exception of adequately treated basal or squamous cell carcinoma of the skin or
carcinoma in situ of the cervix.
- Patients with emotional limitations are excluded from study
- Platelets less than 100 x 109 /L
- Total bilirubin greater than 1.5 x ULRR
- ALT or AST greater than 2.5 x ULRR
- History of bleeding diathesis (i.e., disseminated intravascular coagulation [DIC],
clotting factor deficiency) or long-term anticoagulant therapy (other than
antiplatelet therapy).
- History of hypersensitivity to active or inactive excipients of fulvestrant (i.e.
castor oil or Mannitol).
- Oncotype Dx Recurrence Score of >25.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To assess the pathologic complete response (PCR) rate with 4 months of neo-adjuvant combination endocrine therapy (Anastrazole and Fulvestrant).
Outcome Time Frame:
Duration of study
Safety Issue:
No
Principal Investigator
Qamar Khan, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Kansas
Authority:
United States: Food and Drug Administration
Study ID:
11595
NCT ID:
NCT00921115
Start Date:
May 2009
Completion Date:
February 2014
Related Keywords:
- Invasive Breast Cancer
- hormone receptor positive
- invasive breast cancer
- endocrine therapy
- Anastrazole
- Fulvestrant
- breast tumors
- postmenopausal
- Breast Neoplasms
Name | Location |
|---|---|
| University of Kansas Medical Center | Kansas City, Kansas 66160-7353 |
